jrb006

Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Room 623
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis from the International Phase III ESPAC-3 Clinical Trial
  2. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors
  3. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells
  4. CRISPR knockout of the HuR gene causes a xenograft lethal phenotype
  5. Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas
  6. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
  7. Therapeutic implications of molecular subtyping for pancreatic cancer
  8. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer
  9. DNA repair, overview
  10. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment
  11. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative
  12. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
  13. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR
  14. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells
  15. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy
  16. Delivery of Therapeutics Targeting the mRNA Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth
  17. The landscape of pancreatic cancer therapeutic resistance mechanisms
  18. Personalized therapy for Pancreatic Cancer: Do we need better targets, arrows, or both?
  19. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
  20. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells